October 27, 2017
Longevity Biotech Awarded Grant From National Multiple Sclerosis Society to Evaluate LBT-3627 as a Novel Drug Candidate for Multiple Sclerosis
Longevity Biotech, Inc. (LBT) has received an award from the National Multiple Sclerosis Society through Fast Forward, the Society’s commercial research funding program, to evaluate LBT-3627 in preclinical models as a potential disease-modifying therapeutic agent.